Anxiety treatment serving Boca Raton — exposure-based CBT, in-house psychiatry.

RECO Health's Delray Beach campus sits 20 minutes north of Mizner Park on Federal Highway, close enough that Boca Raton residents attend PHP or IOP without relocating. Anxiety care is disorder-specific from intake forward: GAD-7, PDSS, LSAS, or Y-BOCS establishes a baseline; in-house psychiatry prescribes SSRIs at anxiety-appropriate doses (sertraline 150-200 mg, escitalopram 20 mg); and disorder-matched exposure therapy — ERP for OCD, interoceptive exposure for panic, in-vivo exposure for social anxiety — is the core of the therapy work. Benzodiazepines are used judiciously and never as a substitute for the exposure protocol.

For clients living in Boca Raton — Mizner Park, Royal Palm Place, Downtown Boca, Boca West, or up along Highland Beach — RECO Health’s Delray Beach campus sits eleven miles north on Federal Highway, roughly a 20-minute drive. That distance is short enough that partial hospitalization and intensive outpatient care fit around a daily life rather than requiring temporary relocation. Anxiety disorders are treatable, and the treatment that works is specific: what follows is how RECO Health’s anxiety treatment program is actually structured at the psychiatric and therapy levels.

Disorder-specific assessment before treatment starts

“Anxiety” is a symptom, not a diagnosis. Before a treatment plan is written, RECO Health’s intake clinicians complete a structured diagnostic assessment that names the primary DSM-5-TR condition driving the presentation. Generalized anxiety disorder, panic disorder, social anxiety disorder, and obsessive-compulsive disorder look superficially similar but respond to different exposure structures; running any of them as generic “anxiety group” produces poor outcomes.

The instruments matter. GAD-7 quantifies generalized anxiety severity and tracks response over time. PDSS captures panic frequency, distress, and avoidance. LSAS separates performance from interaction fears in social anxiety. Y-BOCS establishes obsession and compulsion burden in OCD, and it is the scale the ERP evidence base is built around. Where trauma is a driver, PCL-5 is added; where mood is comorbid, PHQ-9 runs in parallel; ASRS screens for ADHD when concentration complaints are prominent.

Every treatment plan at RECO names the primary diagnosis, the co-occurring conditions being treated in parallel, and the outcome measure that will be repeated at defined intervals. That structure is what allows a program to know whether it is working — and to change course when it is not.

SSRI pharmacotherapy at anxiety-appropriate doses

Sertraline, escitalopram, paroxetine, and fluoxetine all carry FDA approval for one or more anxiety disorders and are first-line pharmacologic treatment across GAD, panic, social anxiety, and OCD. RECO Health’s in-house psychiatry team prescribes them at doses calibrated to anxiety response rather than depression response — sertraline 150-200 mg, escitalopram 20 mg, fluoxetine 60-80 mg for OCD. Anxiety-effective dosing typically sits at the upper end of the depression range, and clients whose prior trials failed at 50 mg of sertraline often respond once they reach an adequate dose.

Initial titration is deliberately slow. SSRIs can produce a paradoxical activation in the first ten to fourteen days — restlessness, worsened anxiety, sleep disruption — that predicts non-adherence unless it is anticipated, explained, and managed. Starting at half-doses and titrating over two to four weeks reduces early dropout materially and is the standard on-service protocol.

Augmentation and adjuncts have defined roles. Buspirone is a reasonable add-on for residual generalized anxiety. Hydroxyzine covers as-needed situational use without benzodiazepine dependence risk. Propranolol has a narrow, useful role in performance anxiety. For treatment-resistant OCD, aripiprazole or risperidone augmentation of an SSRI is trial-supported and used selectively. For clients with a co-occurring depressive component, quetiapine at low dose or the addition of an SNRI is considered on an individual basis.

Exposure-based CBT is the therapy that works

For every anxiety disorder, the evidence base points to exposure-based CBT rather than open-ended supportive talk therapy. RECO’s therapists run disorder-matched protocols, and the group programming is structured to support individual exposure work rather than replace it.

Exposure and Response Prevention is the standard of care for OCD: therapist-guided, hierarchical exposure to obsessional triggers with the client agreeing not to perform the ritual response. Panic disorder is treated with interoceptive exposure — deliberate provocation of feared bodily sensations through breath-holding, hyperventilation, and vestibular spinning — coupled with cognitive work on catastrophic misappraisal. Social anxiety is addressed through graded in-vivo exposures such as initiating conversations, giving structured talks, and tolerating perceived scrutiny, with cognitive restructuring targeting probability and cost distortions.

Acceptance and Commitment Therapy (ACT), Motivational Interviewing (MI), and DBT skills modules are integrated where they add value: values-based behavioral activation, distress tolerance, emotion regulation, cognitive defusion, and mindfulness-based attention training. The load-bearing structure, however, is exposure. Programs that dilute it into general talk therapy — however well-intentioned — produce short-term relief without durable change in avoidance behavior or in the threat appraisal that maintains the disorder.

Why we don’t lean on benzodiazepines

Benzodiazepines relieve acute anxiety fast, and that is precisely why they undermine treatment. Extinction learning — the mechanism that makes exposure therapy work — requires the client to experience anxiety and to learn, through repeated non-catastrophic exposures, that it subsides on its own. Blocking that experience with alprazolam or clonazepam blocks the learning.

The risk profile is also material. A significant share of RECO Health’s clients carry a substance use disorder history, and benzodiazepines have a well-documented dependence and cross-tolerance trajectory in that population. Prescribing them alongside an SSRI-plus-CBT regimen for someone in recovery from alcohol or opioid use disorder — where naltrexone or buprenorphine may already be part of the regimen — is a step backward.

Where situational bridging is genuinely needed, hydroxyzine, gabapentin, and short courses of a low-dose beta-blocker cover most use cases without a dependence trajectory. Benzodiazepines are used judiciously in clients with no substance use history when clinically indicated, and never as a substitute for doing the therapy.

What to expect on your first visit

Intake at RECO Health typically runs two to three hours. A psychiatric provider completes a full diagnostic interview covering current symptoms, prior treatment history, medication history including what worked and what did not, family psychiatric history, medical comorbidities, and a structured substance use screen. GAD-7, PHQ-9, and the disorder-specific instrument identified during the interview are administered as a baseline against which response will be tracked.

For clients presenting with an anxiety disorder alongside alcohol or opioid use disorder — a common combination — intake also evaluates whether medically supervised withdrawal is indicated (CIWA-Ar for alcohol, COWS for opioids) before the outpatient anxiety protocol begins. Untreated withdrawal states produce sympathetic activation clinically indistinguishable from panic; layering exposure therapy on top of that state is unproductive.

By the end of intake, clients leave with a working DSM-5-TR diagnosis, a medication plan if pharmacotherapy is indicated, a level-of-care recommendation (PHP or IOP) framed against the ASAM Criteria dimensions where a co-occurring SUD is present, and a therapy assignment matched to the primary anxiety condition. Family members can be included in the intake conversation when the client consents.

Insurance and admissions from Boca Raton

RECO Health is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Insurance verification runs the same business day for most clients and includes confirmation of PHP and IOP benefits, expected copay or coinsurance, and any prior authorization requirements for medications or higher levels of care. The admissions team walks Boca Raton residents through the process by phone.

The drive from most of Boca Raton to the Delray Beach campus is roughly 20 minutes north on Federal Highway or I-95. For clients whose transportation is unreliable during the first weeks of treatment — a common issue during medication titration — admissions can help coordinate logistics so that PHP attendance does not become the reason the treatment fails.

Serving residents of: Mizner Park, Royal Palm Place, Downtown Boca, Boca West, Highland Beach.